HNK20 monoclonal antibody data

Initial results of a randomized, double-blind, placebo-controlled Phase III trial of HNK20 in 614 infants showed that the trial missed its primary end point, reduction of

Read the full 266 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE